B-MS and WuXi to collaborate on new testing facility
WuXi will build cGMP facility in Shanghai
WuXi PharmaTech will perform stability studies of Bristol-Myers Squibb small-molecule drug candidates as part of a new partnership announced by the companies this week.
Under the agreement, Wuxi PharmaTech, a Chinese pharmaceutical outsourcing company will build a fully cGMP-compliant 25,000ft2 analytical testing facility in Shanghai and store and test stability samples and perform other services for New York-based Bristol-Myers Squibb. Financial terms were not revealed.
‘This agreement will expand the scope of our relationship with WuXi and enhance the presence of Bristol-Myers Squibb in China,’ said Mark Powell, senior vice president, Non-Clinical Development, Bristol-Myers Squibb.